TOP TEN perturbations for NM_000379 (Homo sapiens)

Organism: Homo sapiens
Gene: NM_000379
Selected probe(set): 241994_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of NM_000379 (241994_at) across 5392 perturbations tested by GENEVESTIGATOR:

prostate cancer study 8 (p. canc) / prostate cancer study 8 (ptasc)

Relative Expression (log2-ratio):6.0035124
Number of Samples:3 / 2
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (ptasc)
CD90+ FACS sorted prostate tumor-associated stromal cell (ptasc) samples from patients with primary prostate cancer collected after radical prostatectomy.

lung adenocarcinoma study 6 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):5.5142145
Number of Samples:8 / 20
Experimental lung adenocarcinoma study 6 (EML4-ALK)
Primary tumor sample from patients with stage II adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

ovarian tumor study 28 (clear cell adenocarcinoma) / ovarian tumor study 28 (adenocarcinoma)

Relative Expression (log2-ratio):5.224086
Number of Samples:6 / 3
Experimental ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.
Control ovarian tumor study 28 (adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with adenocarcinoma.

ovulation study 1 / proliferative phase endometrium tissue

Relative Expression (log2-ratio):5.180064
Number of Samples:3 / 4
Experimental ovulation study 1
Early secretory phase (ESE) endometrium tissue.
Control proliferative phase endometrium tissue
Proliferative phase (PE) endometrium tissue.

lung adenocarcinoma study 5 (EML4-ALK) / adjacent lung tissue

Relative Expression (log2-ratio):5.0239563
Number of Samples:3 / 20
Experimental lung adenocarcinoma study 5 (EML4-ALK)
Primary tumor sample from patients with stage I adenocarcinoma carrying the EML4-ALK-fusion.
Control adjacent lung tissue
Adjacent and histologically normal, non-tumorous lung tissue samples from patients with lung adenocarcinoma.

prostate cancer study 8 (p. canc) / prostate cancer study 8 (psfmc)

Relative Expression (log2-ratio):4.9978065
Number of Samples:3 / 5
Experimental prostate cancer study 8 (p. canc)
CD26+ FACS sorted prostate neoplasm cell (p. canc) samples from patients with primary prostate cancer collected after radical prostatectomy.
Control prostate cancer study 8 (psfmc)
CD49a+ FACS sorted prostate stromal fibromuscular cell (psfmc) samples from patients with primary prostate cancer collected after radical prostatectomy.

breast cancer study 40 (metastase; ovary) / ovarian tumor study 28 (clear cell adenocarcinoma)

Relative Expression (log2-ratio):-4.9055567
Number of Samples:44 / 6
Experimental breast cancer study 40 (metastase; ovary)
Metastatic tumor tissue obtained from the ovary of female patients with primary breast cancer.
Control ovarian tumor study 28 (clear cell adenocarcinoma)
Primary tumor tissue sample obtained from the ovary of female patients with clear cell adenocarcinoma.

HCC study 18 (very advanced) / normal liver tissue

Relative Expression (log2-ratio):-4.8907013
Number of Samples:3 / 10
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control normal liver tissue
Normal liver tissue samples obtained from the healthy livers of patients undergoing resection for hepatic hemangioma, focal nodular hyperplasia, adenoma/cystadenoma, neuroendocrine tumor, and living donor liver transplantation.

HCC study 18 (very advanced) / dysplastic liver nodule study 1

Relative Expression (log2-ratio):-4.78386
Number of Samples:3 / 17
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control dysplastic liver nodule study 1
Dysplastic nodule tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.

HCC study 18 (very advanced) / hepatitis C study 10

Relative Expression (log2-ratio):-4.590641
Number of Samples:3 / 13
Experimental HCC study 18 (very advanced)
Tumor tissue samples obtained from liver of patients with very advanced hepatocellular carcinoma (HCC) undergoing resection or liver transplantation. Very advanced HCC cases included moderately to poorly differentiated tumors with macrovascular invasion or diffuse liver involvement. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.
Control hepatitis C study 10
Cirrhotic tissue samples obtained from liver of HCV infected patients undergoing resection or liver transplantation. Ten out of 13 samples were obtained from patients with hepatocellular carcinoma. Patients positive for HBV markers, with history of alcohol consumption, nonalcoholic steatohepatitis, hemochromatosis, other chronic liver diseases or prior locoregional treatment were excluded.